Shipman CM - Search Results

1

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.

Shipman CM, Vanderkerken K, Rogers MJ, Lippitt JM, Asosingh K, Hughes DE, Van Camp B, Russell RG, Croucher PI. Shipman CM, et al. Br J Haematol. 2000 Oct;111(1):283-6. doi: 10.1046/j.1365-2141.2000.02310.x. Br J Haematol. 2000. PMID: 11091214 Free article.

2

The pharmacology of bisphosphonates and new insights into their mechanisms of action.

Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, Croucher PI, Shipman C, Fleisch HA. Russell RG, et al. J Bone Miner Res. 1999 Oct;14 Suppl 2:53-65. doi: 10.1002/jbmr.5650140212. J Bone Miner Res. 1999. PMID: 10510215 Free article. Review.

3

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Shipman CM, et al. Br J Haematol. 1997 Sep;98(3):665-72. doi: 10.1046/j.1365-2141.1997.2713086.x. Br J Haematol. 1997. PMID: 9332325 Free article.

4

The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway.

Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. Shipman CM, et al. Cancer Res. 1998 Dec 1;58(23):5294-7. Cancer Res. 1998. PMID: 9850051

5

Bisphosphonates--mechanisms of action in multiple myeloma.

Shipman CM, Rogers MJ, Vanderkerken K, Van Camp B, Graham R, Russell G, Croucher PI. Shipman CM, et al. Acta Oncol. 2000;39(7):829-35. doi: 10.1080/028418600750063587. Acta Oncol. 2000. PMID: 11145441

6

The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel.

Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. Jagdev SP, et al. Among authors: shipman cm. Br J Cancer. 2001 Apr 20;84(8):1126-34. doi: 10.1054/bjoc.2001.1727. Br J Cancer. 2001. PMID: 11308265 Free PMC article.

7

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.

Croucher PI, Shipman CM, Van Camp B, Vanderkerken K. Croucher PI, et al. Among authors: shipman cm. Cancer. 2003 Feb 1;97(3 Suppl):818-24. doi: 10.1002/cncr.11125. Cancer. 2003. PMID: 12548581 Free article.

8

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.

Shipman CM, Croucher PI. Shipman CM, et al. Cancer Res. 2003 Mar 1;63(5):912-6. Cancer Res. 2003. PMID: 12615702

9

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K. Croucher PI, et al. Among authors: shipman cm. J Bone Miner Res. 2003 Mar;18(3):482-92. doi: 10.1359/jbmr.2003.18.3.482. J Bone Miner Res. 2003. PMID: 12619933 Free article.

10

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P. Vanderkerken K, et al. Cancer Res. 2003 Jan 15;63(2):287-9. Cancer Res. 2003. PMID: 12543775

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters